Zenyaku Kogyo
5
8M
3
0.07
1
0.40
- Areas of investment
Summary
Zenyaku Kogyo appeared to be the Corporate Investor, which was created in 1950. The venture was found in Asia in Japan. The main department of described Corporate Investor is located in the Tokyo.
Among the most successful fund investment fields, there are Medical, Health Care. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Theraclone Sciences. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 5 - 10 millions dollars. The important activity for fund was in 2013.
The standard case for the fund is to invest in rounds with 6 partakers. Despite the Zenyaku Kogyo, startups are often financed by MPM Capital, HealthCare Ventures, Canaan Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, ReproCELL, Nissei Capital. In the next rounds fund is usually obtained by Tohoku University Venture Partners, Silicon Valley Bank, ReproCELL.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 1
- Rounds per year
- 0.07
- Follow on index
- 0.40
- Investments by industry
- Biotechnology (5)
- Health Care (4)
- Therapeutics (2)
- Medical (2)
- Drug Delivery (2) Show 5 more
- Investments by region
-
- Japan (3)
- United States (2)
- Peak activity year
- 2011
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Group Appearance index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Theraclone Sciences | 08 Sep 2011 | Decision/Risk Analysis, Biotechnology, Drug Delivery, Health Care, Medical, Therapeutics | Early Stage Venture | 10M | United States, Washington, Seattle |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.